I am not a doctor, ours is a pediatric study, theirs is for adults, they have another phase 2/3 pediatric study in progress, it should be compared with that when the data comes out
https://www.anavex.com/anavex-life-...he-treatment-of-adult-patients-with-rett-syn/
https://www.neurenpharma.com/irm/PD...ificantclinicalbenefitinpediatricRettsyndrome
https://www.clinicaltrials.gov/ct2/...&cond=Rett Syndrome&draw=2&rank=1
ANAVEX MEETS ENDPOINTS PHASE2 RETT, page-3
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$16.71 |
Change
-0.590(3.41%) |
Mkt cap ! $2.135B | |||
| Open | High | Low | Value | Volume |
| $17.50 | $17.55 | $16.57 | $10.01M | 594.0K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 598 | $16.70 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $16.87 | 1676 | 1 |
View Market Depth
| Last trade - 16.10pm 15/11/2024 (20 minute delay) ? |
| NEU (ASX) Chart |